$82.4 Million is the total value of CAXTON CORP's 25 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -111,898 | -100.0% | -0.18% | – |
CACC | Exit | CREDIT ACCEP CORP MICH | $0 | – | -459 | -100.0% | -0.19% | – |
SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -111,217 | -100.0% | -0.20% | – |
FPACU | Exit | FAR PT ACQUISITION CORPunit 06/01/2025 | $0 | – | -23,030 | -100.0% | -0.22% | – |
CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -72,967 | -100.0% | -0.26% | – |
TPIV | Exit | TAPIMMUNE INC | $0 | – | -81,540 | -100.0% | -0.68% | – |
UHAL | Exit | AMERCO | $0 | – | -2,700 | -100.0% | -0.89% | – |
PCG | Exit | PG&E CORP | $0 | – | -22,500 | -100.0% | -0.96% | – |
SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -51,279 | -100.0% | -13.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
CM FIN INC | 16 | Q1 2019 | 7.8% |
SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.